The ONWARDS trial programme confirmed that icodec efficacy profile was non-inferior or even superior (i.e., in T2DM insulin-naïve patients) to the currently available basal insulins, with similar glycemic control and comparable rates of hypoglycemic events, especially for T2DM patients. Here, INS is linked to type 2 diabetes mellitus.